Characteristics, progression-free survival, and overall survival of patients in the REGULATE Trial
| Patient . | Age (y) . | Karnofsky performance score . | Recursive partitioning analysis class . | Progression-free survival, mo (surgery) . | Overall survival, mo (surgery) . | Progression-free survival, mo (vaccine 1) . | Overall survival, mo (vaccine 1) . |
|---|---|---|---|---|---|---|---|
| 1 | 43 | 100 | III | > 42.0 | > 42.0 | > 38.0 | > 38.0 |
| 2 | 45 | 100 | III | 7.2 | 22.1 | 2.8 | 17.7 |
| 3 | 55 | 100 | IV | 5.4 | 15.5 | 1.8 | 11.8 |
| 4 | 49 | 90 | III | 27.2 | > 35.1 | 23.5 | > 31.5 |
| 5 | 20 | 80 | IV | > 27.5 | > 31.1 | > 24.3 | > 27.9 |
| 6 | 62 | 90 | IV | > 26.4 | > 26.4 | > 22.8 | > 22.8 |
| Median | 47 | 95 | 27.2 | Not reached | 23.5 | Not reached |
| Patient . | Age (y) . | Karnofsky performance score . | Recursive partitioning analysis class . | Progression-free survival, mo (surgery) . | Overall survival, mo (surgery) . | Progression-free survival, mo (vaccine 1) . | Overall survival, mo (vaccine 1) . |
|---|---|---|---|---|---|---|---|
| 1 | 43 | 100 | III | > 42.0 | > 42.0 | > 38.0 | > 38.0 |
| 2 | 45 | 100 | III | 7.2 | 22.1 | 2.8 | 17.7 |
| 3 | 55 | 100 | IV | 5.4 | 15.5 | 1.8 | 11.8 |
| 4 | 49 | 90 | III | 27.2 | > 35.1 | 23.5 | > 31.5 |
| 5 | 20 | 80 | IV | > 27.5 | > 31.1 | > 24.3 | > 27.9 |
| 6 | 62 | 90 | IV | > 26.4 | > 26.4 | > 22.8 | > 22.8 |
| Median | 47 | 95 | 27.2 | Not reached | 23.5 | Not reached |